Dedifferentiated gastrointestinal stromal tumor: Recent advances

Ann Diagn Pathol. 2019 Apr:39:118-124. doi: 10.1016/j.anndiagpath.2018.12.005. Epub 2018 Dec 18.

Abstract

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal lesions of the gastrointestinal tract. A small minority of GISTs exhibit morphologic and phenotypic changes and differentiate into an unusual phenotype through the process of dedifferentiation. Dedifferentiation can occur either de novo or after prolonged treatment with imatinib, a selective tyrosine kinase inhibitor. GISTs can present with various morphologies including rhabdomyosarcoma, angiosarcoma, or undifferentiated pleomorphic sarcoma. The unusual histologic and immunohistochemical characteristics of these tumors can be diagnostically challenging. Therefore, it is essential that the pathologists recognize GISTs with unusual morphology and be aware of the dedifferentiation process. This review aims to provide an overview of the morphologic and molecular features of dedifferentiated GISTs. Additionally, we discuss diagnostic dilemmas and recent immunohistochemical markers that are useful in distinguishing dedifferentiated GISTs from other gastrointestinal tumors.

Keywords: Dedifferentiation; GIST; Mesenchymal neoplasm; Molecular markers.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism*
  • Cell Dedifferentiation / drug effects
  • Gastrointestinal Neoplasms / diagnosis*
  • Gastrointestinal Neoplasms / drug therapy
  • Gastrointestinal Neoplasms / metabolism
  • Gastrointestinal Neoplasms / pathology
  • Gastrointestinal Stromal Tumors / diagnosis*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / metabolism
  • Gastrointestinal Stromal Tumors / pathology
  • Humans
  • Imatinib Mesylate / pharmacology
  • Imatinib Mesylate / therapeutic use
  • Immunohistochemistry

Substances

  • Biomarkers, Tumor
  • Imatinib Mesylate